胶束载体系统的基本原理及临床试验

Y. Matsumura
{"title":"胶束载体系统的基本原理及临床试验","authors":"Y. Matsumura","doi":"10.1109/ICMENS.2004.38","DOIUrl":null,"url":null,"abstract":"NK911 is the first successful polymeric micelle system directed to remarkable accumulation in solid tumor through 5PR affect. The micelle consists of block copolymer of polyethylene glycol (PEG) and poly (aspartic acid) partially conjugated doxorubicin. The main objectives of this phase I study were to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and the recommended dose (RD) for phase II given every 3 weeks as a 10 mg DXR equivalent/min iv infusion to patients with solid tumors. Dose escalation is based on the accelerated titration method followed by a modified Fibonacci method. The starting dose was 6.0 mg/m2 (1/10 of rat LD10). No intrapatient dose escalation was allowed.","PeriodicalId":344661,"journal":{"name":"2004 International Conference on MEMS, NANO and Smart Systems (ICMENS'04)","volume":"22 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2004-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Basic Aspects and Clinical Trials of Micelle Carrier System\",\"authors\":\"Y. Matsumura\",\"doi\":\"10.1109/ICMENS.2004.38\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"NK911 is the first successful polymeric micelle system directed to remarkable accumulation in solid tumor through 5PR affect. The micelle consists of block copolymer of polyethylene glycol (PEG) and poly (aspartic acid) partially conjugated doxorubicin. The main objectives of this phase I study were to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and the recommended dose (RD) for phase II given every 3 weeks as a 10 mg DXR equivalent/min iv infusion to patients with solid tumors. Dose escalation is based on the accelerated titration method followed by a modified Fibonacci method. The starting dose was 6.0 mg/m2 (1/10 of rat LD10). No intrapatient dose escalation was allowed.\",\"PeriodicalId\":344661,\"journal\":{\"name\":\"2004 International Conference on MEMS, NANO and Smart Systems (ICMENS'04)\",\"volume\":\"22 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2004-08-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"2004 International Conference on MEMS, NANO and Smart Systems (ICMENS'04)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1109/ICMENS.2004.38\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"2004 International Conference on MEMS, NANO and Smart Systems (ICMENS'04)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1109/ICMENS.2004.38","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

摘要

NK911是第一个成功的聚合物胶束系统,通过5PR影响在实体肿瘤中显著积累。该胶束由聚乙二醇(PEG)和聚天冬氨酸部分偶联的阿霉素嵌段共聚物组成。这项I期研究的主要目的是确定最大耐受剂量(MTD)、剂量限制性毒性(dlt)和II期推荐剂量(RD),每3周给实体肿瘤患者静脉输注10mg DXR当量/分钟。剂量递增是基于加速滴定法,然后是改进的斐波那契方法。起始剂量为6.0 mg/m2(大鼠LD10的1/10)。不允许在病人体内增加剂量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Basic Aspects and Clinical Trials of Micelle Carrier System
NK911 is the first successful polymeric micelle system directed to remarkable accumulation in solid tumor through 5PR affect. The micelle consists of block copolymer of polyethylene glycol (PEG) and poly (aspartic acid) partially conjugated doxorubicin. The main objectives of this phase I study were to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and the recommended dose (RD) for phase II given every 3 weeks as a 10 mg DXR equivalent/min iv infusion to patients with solid tumors. Dose escalation is based on the accelerated titration method followed by a modified Fibonacci method. The starting dose was 6.0 mg/m2 (1/10 of rat LD10). No intrapatient dose escalation was allowed.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信